Dr. Armaghany on the Importance of the NCI-MATCH Trial in CRC

March 26, 2020
Tannaz Armaghany, MD

Partner | Cancer Centers | <b>Dan L. Duncan Comprehensive Cancer Center</b>

Tannaz Armaghany, MD, discusses the importance of NCI-MATCH trial in colorectal cancer.

Tannaz Armaghany, MD, an assistant professor, Internal Medicine, Hematology and Medical Oncology, at Baylor College of Medicine, discusses the importance of NCI-MATCH trial in colorectal cancer (CRC).

The NCI-MATCH trial was created as a way to increase the efficiency of basket trials and umbrella trials, according to Armaghany. In the trial, patients will undergo genomic sequencing. The treatment arm patients are assigned to will be based on the results of their genomic profile rather than their tumor type, explains Armaghany.

Patients with advanced solid tumors, lymphomas, or myeloma who have progressed on standard therapy or those with rare cancers for which there is no standard therapy available may be eligible for enrollment. The trial could expedite the drug discovery process and enhance the treatment pipeline in oncology, which is of great importance in an aggressive malignancy such as mCRC, concludes Armaghany.


x